Y-mabs closes deals in China and Europe for the firm's two drugs against pediatric cancer

According to these new deals, Y-mabs will pass on responsibility for the distribution of its drugs danyelza and omburtamab in China and Europe – the task will instead be passed onto various partners.

Photo: Kelly Davidson Photography

The Danish but US-listed biotech firm Y-mabs has entered two new partnerships in China and Eastern Europe, respectively.

The deals revolve around the firm's drugs omburtamab and naxitamab.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Latest news

See all jobs